Skip to content
Review Open access

Spasmolytic Polypeptide‐Expressing Metaplasia in Chronic Atrophic Gastritis and Its Role in the Progression From Gastritis to Gastric Cancer

Jul 2026 · Journal of Digestive Diseases · Vol 27, pp. 190 - 204 · 0 citations · 124 references
Medicine

TL;DR

This review summarizes current knowledge on cellular plasticity, lineage dynamics, and molecular mechanisms underlying SPEM formation and progression in CAG and focuses on recent advances in oxyntic atrophy, immune cell and inflammation, as well as oxidative stress in gastric epithelial remodeling.

Abstract

Chronic atrophic gastritis (CAG) is a well‐recognized precursor of gastric cancer (GC). Spasmolytic polypeptide‐expressing metaplasia (SPEM) is a key intermediate state during this process, representing a reparative response to gastric mucosal injury, and may promote the development of malignancy under persistent inflammation. Recent studies have suggested that SPEM is not a static lesion but a dynamic and heterogeneous process regulated by epithelial injury, oxyntic atrophy, and chronic inflammation. This review summarizes current knowledge on cellular plasticity, lineage dynamics, and molecular mechanisms underlying SPEM formation and progression in CAG. We focus on recent advances in oxyntic atrophy, immune cell and inflammation, as well as oxidative stress in gastric epithelial remodeling, and highlight emerging evidence implicating ferroptosis, a regulated form of iron‐dependent lipid peroxidation, in gastric mucosal inflammation and SPEM development. By integrating classical models of GC with recent mechanistic insights, we aim to discuss the role of SPEM in CAG‐associated GC risk and to identify potential therapeutic targets related to oxyntic atrophy, inflammation, and ferroptosis. These emerging findings offer new perspectives for future research aiming at risk stratification and precision prevention.

Read PDF

Similar papers

Review Open access Aug 2026

Inflammation as a Unifying Axis: Shared Pathogenic Mechanisms in Coronary Atherosclerosis and Chronic Atrophic Gastritis

Inflammation-targeted strategies are discussed as possible candidate approaches to balance cardiovascular protection, gastrointestinal safety, and gastric oncologic risk in this comorbid setting.

Wenxi Yu, Ai-Lin Hou, Chen Chen et al. · 0 citations
Open access Aug 2026

Piwei Peiyuan Pill Ameliorates Chronic Atrophic Gastritis and Intestinal Metaplasia at Least in Part by Inhibiting the Pellino1/IRAK1/NF‐κB Signaling Axis

Findings suggest that PPP mitigates CAG and attenuates IM at least in part by suppressing the Pellino1/IRAK1/NF‐κB signaling pathway, indicating that it may serve as a promising therapeutic strategy for reducing inflammation‐associated gastric carcinogenesis.

Cheng Zhang, Fei Lu, Ting Ye et al. · 0 citations
Review Aug 2026

Incomplete Intestinal Metaplasia as a High-Risk Clinical Phenotype in Gastric Carcinogenesis: Implications for Surveillance and Management.

IIM is a biologically unstable, transitional lesion with a markedly elevated risk of progression to gastric adenocarcinoma, warranting its distinction from CIM in clinical practice, and future strategies must integrate IIM subtyping into personalized surveillance protocols to enhance gastric cancer prevention.

Hongfa Wei, Weidong Chen, Xun Chen et al. · 0 citations
Review Open access Aug 2026

Molecular Mechanisms and Biomarkers Driving the Transition From Chronic Atrophic Gastritis to Gastric Cancer

A conceptual model of gastric carcinogenesis as a continuous molecular evolutionary process in which chronic inflammation initiates progressive epigenetic and genetic alterations that promote clonal selection and malignant transformation is supported.

Yerlan Suleimenov, Ainur Samigatova, B. Seksenbayev et al. · 0 citations
Review Open access Aug 2026

Glycolytic reprogramming in precancerous lesions of gastric cancer progression: pathogenesis and therapeutic potential

Precancerous lesions of gastric cancer (PLGC) represent a critical stage preceding the development of gastric cancer. Their progression to gastric cancer remains a significant challenge in clinical prevention and treatment. Recent studies have shown that glycolytic reprogramming is a dynamic and modifiable metabolic pr...

Siying Niu, Heyuan Sun, Zi-Jian Wang et al. · 0 citations
Open access Sep 2026

Berberine Prevents and Reverses Gastric Spasmolytic Polypeptide-Expressing Metaplasia by Modulating M2 Macrophage Polarization

Findings provide preclinical evidence supporting berberine as a candidate therapeutic agent for SPEM by preventing and reversing tamoxifen-induced gastric SPEM by inhibiting M2 macrophage polarization and infiltration and regulating the JAK-STAT/NF-κB pathway and S100A6 expression.

Jia-Lei Li, Shi-Yi Ge, Xing-Xing Zhou et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.